Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + camrelizumab + apatinib as second-line treatment for biliary tract cancer
ChiCTR2000040758Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, camrelizumab and Rivoceranib in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
tegafurcamrelizumabRivoceranib
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2000040758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040758.